China is making waves in the field of obesity drug discovery with the development of a new drug called ecnoglutide. This drug has shown promising results in helping people lose weight, outperforming a placebo in a recent phase III trial. Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the popular obesity drug semaglutide. This new drug targets the production of cyclic adenosine monophosphate, a messenger molecule that helps regulate blood-sugar levels and promotes weight loss.
The study, funded by Chinese drug manufacturer Sciwind Biosciences, involved 664 participants who were either given a weekly injection of a placebo or one of three doses of ecnoglutide. The results were impressive, with those receiving the maximum dose of 2.4 milligrams losing up to 13.8 kilograms over 48 weeks of treatment. Additionally, 92.8% of participants in this group lost at least 5% of their body weight, compared to only 14% in the placebo group. Even after stopping treatment, participants were able to maintain their reduced weight, regaining only around 1% over a 7-week period.
Ecnoglutide not only helps with weight loss but also improves risk factors for heart disease and diabetes, as well as reducing fat in the liver. This drug is just one of many next-generation obesity drugs being developed in China. According to Dr. Daniel Drucker from the University of Toronto, there are dozens of GLP-1 drugs in the pipeline, with more innovations to come.
One such drug is mazdutide, developed by Eli Lilly and manufactured by Innovent Biologics in China. This drug has shown promising results in helping people lose up to 15% of their body weight over 36 weeks and reducing the risk of cardiovascular diseases. Other trials are underway to test mazdutide’s effectiveness in treating sleep apnea and type 2 diabetes.
In addition to ecnoglutide and mazdutide, China is also developing a triple agonist drug known as UBT251, which mimics GLP-1, glucagon, and gastric inhibitory polypeptide (GIP). This drug is in the early stages of testing to address weight loss and treat chronic kidney disease, fatty liver disease, and type 2 diabetes.
Overall, China’s advancements in obesity drug discovery are paving the way for more tailored treatments that target specific conditions associated with obesity and diabetes. With the development of new drugs like ecnoglutide, mazdutide, and UBT251, personalized medicine for obesity and diabetes is becoming more accessible. It’s clear that China is at the forefront of innovative drug development in the fight against obesity and related health conditions.
